NASDAQ: LXEO
Lexeo Therapeutics Inc Stock Ownership - Who owns Lexeo Therapeutics?

Insider buying vs selling

Have Lexeo Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Richard Nolan TownsendChief Executive Officer2025-11-181,127$9.27
$10.45kSell
Eric AdlerChief Medical Officer2025-11-18615$9.27
$5.70kSell
Jenny RobertsonChief Legal Officer2025-11-18549$9.27
$5.09kSell
Tai Sandi SeeChief Development Officer2025-11-18386$9.27
$3.58kSell
Eric AdlerChief Medical Officer2025-10-1738$9.56
$363.32Sell
Richard Nolan TownsendChief Executive Officer2025-10-1712,985$8.94
$116.02kSell
Jose Manuel OteroChief Technical Officer2025-10-172,091$8.94
$18.68kSell
Jose Manuel OteroChief Technical Officer2025-10-1724$9.56
$229.46Sell
Jenny RobertsonChief Legal Officer2025-10-173,486$8.94
$31.15kSell
Jenny RobertsonChief Legal Officer2025-10-1740$9.56
$382.44Sell

1 of 4

LXEO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LXEO insiders and whales buy or sell their stock.

LXEO Shareholders

What type of owners hold Lexeo Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Janus Henderson Group PLC8.37%6,105,527$46.22MInstitution
Frazier Life Sciences Management LP6.06%4,424,725$33.50MInstitution
Balyasny Asset Management LP5.36%3,913,788$29.63MInstitution
Affinity Asset Advisors LLC5.30%3,870,527$29.30MInstitution
Citadel Advisors LLC5.10%3,719,043$28.15MInstitution
Vestal Point Capital LP4.45%3,250,000$24.60MInstitution
Woodline Partners LP3.52%2,572,162$19.47MInstitution
Longitude Capital Partners IV LLC3.52%2,567,100$19.43MInsider
Millennium Management LLC3.17%2,313,642$17.51MInstitution
Vanguard Group Inc3.05%2,226,290$16.85MInstitution

1 of 3

LXEO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LXEO67.63%9.87%Net SellingNet Selling
LBRX71.88%28.12%Net Buying
DNA9.27%90.73%Net SellingNet Selling
SLS23.11%6.55%Net SellingNet Selling
KROS79.60%20.40%Net SellingNet Selling

Lexeo Therapeutics Stock Ownership FAQ

Who owns Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ: LXEO) is owned by 67.63% institutional shareholders, 9.87% Lexeo Therapeutics insiders, and 22.50% retail investors. Longitude Capital Partners IV LLC is the largest individual Lexeo Therapeutics shareholder, owning 2.57M shares representing 3.52% of the company. Longitude Capital Partners IV LLC's Lexeo Therapeutics shares are currently valued at $19.02M.

If you're new to stock investing, here's how to buy Lexeo Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.